Baader Bank Aktiengesellschaft Has $2.07 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Baader Bank Aktiengesellschaft lifted its stake in Pfizer Inc. (NYSE:PFE) by 27.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 77,765 shares of the biopharmaceutical company’s stock after purchasing an additional 16,852 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Pfizer were worth $2,073,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Clifford Swan Investment Counsel LLC lifted its position in shares of Pfizer by 4.7% in the fourth quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after purchasing an additional 18,611 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after acquiring an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC purchased a new stake in shares of Pfizer during the fourth quarter worth $255,000. KLCM Advisors Inc. grew its stake in Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after purchasing an additional 74,487 shares in the last quarter. Finally, Farmers Trust Co. grew its stake in shares of Pfizer by 2.0% in the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock valued at $6,503,000 after buying an additional 4,410 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock traded up $0.11 during trading hours on Thursday, hitting $28.93. 40,061,284 shares of the stock were exchanged, compared to its average volume of 43,043,617. The stock has a market capitalization of $163.93 billion, a P/E ratio of -479.92, a P/E/G ratio of 1.20 and a beta of 0.63. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The business’s 50-day moving average is $27.13 and its two-hundred day moving average is $28.04. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the prior year, the business earned $1.23 earnings per share. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.81%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Finally, Morgan Stanley lifted their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.